Invivyd, Inc. (IVVD)

NASDAQ: IVVD · IEX Real-Time Price · USD
2.97
-0.30 (-9.17%)
At close: Sep 23, 2022 4:00 PM
2.93
-0.04 (-1.35%)
After-hours: Sep 23, 2022 7:46 PM EDT
-9.17%
Market Cap 323.23M
Revenue (ttm) n/a
Net Income (ttm) -295.07M
Shares Out 108.83M
EPS (ttm) -2.63
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 359,990
Open 3.21
Previous Close 3.27
Day's Range 2.93 - 3.24
52-Week Range 2.41 - 78.82
Beta n/a
Analysts n/a
Price Target 3.91 (+31.6%)
Earnings Date Sep 19, 2022

About IVVD

Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatment and prevention of coronavirus disease. Adagio Therapeutics, Inc. has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research In... [Read more...]

Industry Biotechnology
IPO Date Aug 6, 2021
Employees 101
Stock Exchange NASDAQ
Ticker Symbol IVVD
Full Company Profile

News

Invivyd Announces Multiple Next Generation COVID-19 Antibody Candidates and Selects Combination for Clinical Advancem...

WALTHAM, Mass., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Invivyd, (Nasdaq: IVVD beginning September 13), formerly Adagio Therapeutics (Nasdaq: ADGI), a clinical-stage biopharmaceutical company on a mission to...

1 week ago - GlobeNewsWire

Adagio Therapeutics Announces Corporate Name Change to Invivyd

WALTHAM, Mass., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Adagio Therapeutics, (Nasdaq: ADGI), a clinical-stage biopharmaceutical company on a mission to protect humanity from serious viral respiratory disease...

1 week ago - GlobeNewsWire

Adagio Therapeutics to Participate in Upcoming Investor Conferences

WALTHAM, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Adagio Therapeutics, Inc. (Nasdaq: ADGI), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of dif...

2 weeks ago - GlobeNewsWire

Adagio Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights

$475 Million in Cash and Cash Equivalents to Support Operating Runway into Second Quarter of 2024

1 month ago - GlobeNewsWire

Mithril Capital's Ajay Royan Sends Letter Thanking Adagio Therapeutics Shareholders for Support of Successful Proxy C...

AUSTIN, Texas--(BUSINESS WIRE)--Mithril Capital Management LLC (“Mithril”), a founding investor in and the leader of a consortium of investors that represented approximately 49% of the outstanding share...

2 months ago - Business Wire

Adagio Announces David Hering Named Permanent Chief Executive Officer and Director

WALTHAM, Mass., July 05, 2022 (GLOBE NEWSWIRE) -- Adagio Therapeutics, Inc. (Nasdaq: ADGI), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of anti...

2 months ago - GlobeNewsWire

(ADGI) News: Did You Lose Money on Your Adagio Therapeutics Investment? Stock Price has Plummeted Since IPO - Contact...

San Diego, California--(Newsfile Corp. - July 3, 2022) - Shareholder rights law firm Johnson Fistel, LLP (www.JohnsonFistel.com) is investigating whether Adagio Therapeutics, Inc. ("Adagio " or the "Com...

2 months ago - Newsfile Corp

Adagio Announces Results of Annual Meeting of Stockholders and Evolution of the Board of Directors

Marc Elia Named Chair of the Board of Directors Marc Elia Named Chair of the Board of Directors

2 months ago - GlobeNewsWire

Adagio Therapeutics Reports First Quarter 2022 Financial Results

$532.2 Million in Total Cash at Quarter End; Strong Balance Sheet Expected to Support Operations into Second Half of 2024

4 months ago - GlobeNewsWire

Adagio Pauses FDA Emergency Use Request For Its COVID-19 Therapy

Adagio Therapeutics Inc (NASDAQ: ADGI) provided an update on the anticipated timing for its Emergency Use Authorization (EUA) request for adintrevimab (ADG20) for the prevention and treatment of COVID-1...

5 months ago - Benzinga

Adagio Therapeutics Provides Update on Timing of Adintrevimab EUA Request

WALTHAM, Mass., April 14, 2022 (GLOBE NEWSWIRE) -- Adagio Therapeutics, Inc. (Nasdaq: ADGI), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of ant...

5 months ago - GlobeNewsWire

Adagio's (ADGI) COVID-19 Antibody Meets Goals in Studies

The stock price of Adagio (ADGI) surge after it reports positive preliminary data from the phase II/III studies, which evaluate its monoclonal antibody for the prevention and treatment of COVID-19.

5 months ago - Zacks Investment Research

Top Penny Stocks Today: Why Are ADGI, DRCT, VYNT, NAOV, GERN and SNOA Rising Today?

Penny stocks are a hot subject today with several of the top companies in the market seeing major gains on Wednesday and we know why! The post Top Penny Stocks Today: Why Are ADGI, DRCT, VYNT, NAOV, GER...

Other symbols: DRCTGERNNAOVSNOAVYNT
5 months ago - InvestorPlace

Why Is Adagio Therapeutics (ADGI) Stock Up Today?

Adagio recently announced that lab data has proven the effectiveness of its antibody treatment. ADGI stock is up more than 40% on the news.

5 months ago - InvestorPlace

Adagio's COVID-19 Antibody Meets Primary Goals Across Pre & Post-Exposure Prophylaxis, Treatment

Adagio Therapeutics Inc's (NASDAQ: ADGI) Phase 2/3 trials evaluating 300 mg adintrevimab (ADG20) as pre-and-post-exposure prophylaxis (EVADE) and treatment (STAMP) for COVID-19 have met its primary endp...

5 months ago - Benzinga

Why Adagio Therapeutics Stock Is Soaring Today.

Investors are reacting to better than expected clinical trial results for its COVID-19 treatment candidate.

5 months ago - The Motley Fool

Why Adagio Therapeutics Stock Is Soaring Today

Adagio Therapeutics Inc (NASDAQ: ADGI) is trading higher Wednesday after the company announced its investigational drug adintrevimab (ADG20) was the first monoclonal antibody to meet primary endpoints w...

5 months ago - Benzinga

Adagio Stock Spikes on New Data, but Its Omicron Problems Remain

Adagio Therapeutics says it will seek an emergency use authorization for its Covid-19 antibody, known as ADG20, in the second quarter.

5 months ago - Barrons

Adagio's stock jumps as company says it will seek authorization for COVID-19 antibody treatment

Shares of Adagio Therapeutics Inc. ADGI, +1.05% soared 53.2% in premarket trading on Wednesday after the company said its experimental COVID-19 monoclonal antibody worked as a treatment and for pre-and-...

5 months ago - Market Watch

These 2 Nasdaq Biotech Stocks Are Soaring Wednesday Morning

Markets looked to take a breather after a huge surge in recent weeks.

Other symbols: VIR
5 months ago - The Motley Fool

Adagio Therapeutics Announces ADG20 (adintrevimab) is the First Monoclonal Antibody to Meet Primary Endpoints with St...

Risk of symptomatic COVID-19 was reduced by 71% compared to placebo in  pre-exposure prophylaxis and 75% compared to placebo in post-exposure prophylaxis

5 months ago - GlobeNewsWire

Adagio Therapeutics, Inc. Announces 2022 Annual Meeting of Stockholders

WALTHAM, Mass., March 18, 2022 (GLOBE NEWSWIRE) -- Adagio Therapeutics, Inc. (NASDAQ: ADGI) today announced that it will hold its 2022 Annual Meeting of Stockholders virtually at 8:30 a.m. Eastern Time ...

6 months ago - GlobeNewsWire

Adagio Therapeutics Announces David Hering Appointed Interim Chief Executive Officer

WALTHAM, Mass., Feb. 23, 2022 (GLOBE NEWSWIRE) -- Adagio Therapeutics, Inc., (Nasdaq: ADGI), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of ant...

7 months ago - GlobeNewsWire

Adagio Lays Out Development Plans For COVID-19-Focused ADG20 Program

Adagio Therapeutics Inc (NASDAQ: ADGI) has outlined strategic initiatives for its ADG20 program and research efforts to address SARS-CoV-2 and other coronaviruses.  ADG20 is an investigational monoclona...

7 months ago - Benzinga

Adagio Therapeutics Announces ADG20 Development Plans and Pipeline Updates

Multiple Initiatives Undertaken for ADG20 Assessment, Including Analysis of Clinical Data at 300mg Dose and Exploring Higher Doses of ADG20 in the Clinic

7 months ago - GlobeNewsWire